CytoMed Therapeutics Statistics
Total Valuation
GDTC has a market cap or net worth of $24.24 million. The enterprise value is $17.88 million.
| Market Cap | 24.24M |
| Enterprise Value | 17.88M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
GDTC has 11.54 million shares outstanding. The number of shares has increased by 53.29% in one year.
| Shares Outstanding | 11.54M |
| Shares Change (YoY) | +53.29% |
| Shares Change (QoQ) | -7.80% |
| Owned by Insiders (%) | 69.27% |
| Owned by Institutions (%) | 0.04% |
| Float | 3.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 45.69 |
| PB Ratio | 2.90 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.08, with a Debt / Equity ratio of 0.04.
| Current Ratio | 14.08 |
| Quick Ratio | 14.08 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -79.58 |
Financial Efficiency
Return on equity (ROE) is -69.90% and return on invested capital (ROIC) is -15.71%.
| Return on Equity (ROE) | -69.90% |
| Return on Assets (ROA) | -47.00% |
| Return on Capital (ROIC) | -15.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$111,821 |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GDTC has paid $486 in taxes.
| Income Tax | 486 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.89% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -47.89% |
| 50-Day Moving Average | 2.06 |
| 200-Day Moving Average | 2.86 |
| Relative Strength Index (RSI) | 51.54 |
| Average Volume (20 Days) | 190,191 |
Short Selling Information
The latest short interest is 39,252, so 0.34% of the outstanding shares have been sold short.
| Short Interest | 39,252 |
| Short Previous Month | 38,810 |
| Short % of Shares Out | 0.34% |
| Short % of Float | 1.11% |
| Short Ratio (days to cover) | 5.94 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.37M |
| Pretax Income | -3.07M |
| Net Income | -3.13M |
| EBITDA | -2.75M |
| EBIT | -3.03M |
| Earnings Per Share (EPS) | -$0.29 |
Balance Sheet
The company has $6.69 million in cash and $333,127 in debt, giving a net cash position of $6.36 million or $0.55 per share.
| Cash & Cash Equivalents | 6.69M |
| Total Debt | 333,127 |
| Net Cash | 6.36M |
| Net Cash Per Share | $0.55 |
| Equity (Book Value) | 8.36M |
| Book Value Per Share | 0.72 |
| Working Capital | 6.97M |
Cash Flow
In the last 12 months, operating cash flow was -$2.62 million and capital expenditures -$43,345, giving a free cash flow of -$2.67 million.
| Operating Cash Flow | -2.62M |
| Capital Expenditures | -43,345 |
| Free Cash Flow | -2.67M |
| FCF Per Share | -$0.25 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GDTC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -53.29% |
| Shareholder Yield | -53.29% |
| Earnings Yield | -12.92% |
| FCF Yield | -11.01% |
Analyst Forecast
The average price target for GDTC is $5.00, which is 138.08% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.00 |
| Price Target Difference | 138.08% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |